Efficient HIV Responses in Eastern Europe and Central Asia

Total Page:16

File Type:pdf, Size:1020Kb

Efficient HIV Responses in Eastern Europe and Central Asia Tackling the World’s Fastest- Growing HIV Epidemic HUMAN DEVELOPMENT PERSPECTIVES Tackling the World’s Fastest-Growing HIV Epidemic More Efficient HIV Responses in Eastern Europe and Central Asia Feng Zhao, Clemens Benedikt, and David Wilson, Editors © 2020 International Bank for Reconstruction and Development / The World Bank 1818 H Street NW, Washington, DC 20433 Telephone: 202-473-1000; Internet: www.worldbank.org Some rights reserved 1 2 3 4 23 22 21 20 This work is a product of the staff of The World Bank with external contributions. The findings, interpretations, and conclusions expressed in this work do not necessarily reflect the views of The World Bank, its Board of Executive Directors, or the governments they represent. The World Bank does not guarantee the accuracy of the data included in this work. The boundaries, colors, denomi- nations, and other information shown on any map in this work do not imply any judgment on the part of The World Bank concerning the legal status of any territory or the endorsement or acceptance of such boundaries. Nothing herein shall constitute or be considered to be a limitation upon or waiver of the privi- leges and immunities of The World Bank, all of which are specifically reserved. Rights and Permissions This work is available under the Creative Commons Attribution 3.0 IGO license (CC BY 3.0 IGO) http://creativecommons.org/licenses/by/3.0/igo. Under the Creative Commons Attribution license, you are free to copy, distribute, transmit, and adapt this work, including for commercial purposes, under the following conditions: Attribution—Please cite the work as follows: Zhao, Feng, Clemens Benedikt, and David Wilson, eds. 2020. Tackling the World’s Fastest-Growing HIV Epidemic: More Efficient HIV Responses in Eastern Europe and Central Asia. Human Development Perspectives. Washington, DC: World Bank. doi:10.1596/978- 1-4648-1523-2. License: Creative Commons Attribution CC BY 3.0 IGO Translations—If you create a translation of this work, please add the following disclaimer along with the attribution: This translation was not created by The World Bank and should not be considered an official World Bank translation. The World Bank shall not be liable for any content or error in this translation. Adaptations—If you create an adaptation of this work, please add the following disclaimer along with the attribution: This is an adaptation of an original work by The World Bank. Views and opinions expressed in the adaptation are the sole responsibility of the author or authors of the adaptation and are not endorsed by The World Bank. Third-party content—The World Bank does not necessarily own each component of the content contained within the work. The World Bank therefore does not warrant that the use of any third- party-owned individual component or part contained in the work will not infringe on the rights of those third parties. The risk of claims resulting from such infringement rests solely with you. If you wish to re-use a component of the work, it is your responsibility to determine whether permission is needed for that re-use and to obtain permission from the copyright owner. Examples of compo- nents can include, but are not limited to, tables, figures, or images. All queries on rights and licenses should be addressed to World Bank Publications, The World Bank Group, 1818 H Street NW, Washington, DC 20433, USA; e-mail: [email protected]. ISBN (paper): 978-1-4648-1523-2 ISBN (electronic): 978-1-4648-1524-9 DOI: 10.1596/978-1-4648-1523-2 Cover image: © Theo Hawkins / World Bank. Further permission required for reuse. Cover design: Bill Pragluski, Critical Stages, LLC. Library of Congress Control Number: 2020901026. Human Development Perspectives The books in this series address main and emerging development issues of a global/regional nature through original research and findings in the areas of education, gender, health, nutrition, population, and social protection and jobs. The series is aimed at policy makers and area experts and is over- seen by the Human Development Practice Group Chief Economist. Previous titles in this series Meera Shekar and Barry Popkin, Obesity: Health and Economic Consequences of an Impending Global Challenge (2020). Truman Packard, Ugo Gentilini, Margaret Grosh, Philip O’Keefe, Robert Palacios, David Robalino, and Indhira Santos, Protecting All: Risk Sharing for a Diverse and Diversifying World of Work (2019). Damien de Walque, Risking Your Health: Causes, Consequences, and Interventions to Prevent Risky Behaviors (2014). Rita Almeida, Jere Behrman, and David Robalino, The Right Skills for the Job? Rethinking Training Policies for Workers (2012). Barbara Bruns, Deon Filmer, and Harry Anthony Patrinos, Making Schools Work: New Evidence on Accountability Reforms (2011). Harold Alderman, No Small Matter: The Impact of Poverty, Shocks, and Human Capital Investments in Early Childhood Development (2011). All books in the Human Development Perspectives series are available at https://openknowledge.worldbank.org/handle/10986/2161. Contents Acknowledgments xxi Abbreviations xxv Introduction 1 Feng Zhao, Clemens Benedikt, and Katherine Ward Part I: The Growing Challenge The Fastest-Growing HIV Epidemic in the World 2 A Concentrated but Diversifying Epidemic 4 Ongoing Barriers to Treatment 8 The Rising Importance of Domestic Financing 10 Part II: Using Allocative Efficiency Analysis to Chart the Way Forward Scaling Up Treatment and Prevention 13 Variations in HIV Spending Levels 14 Varying Costs per Person Reached 17 Recommendations 19 Advanced Concentrated HIV Epidemics 23 Notes 23 References 24 vii viii | Contents Chapter 1: Cost-Effectiveness 2.0 27 Improving Allocative Efficiency with Decision Science Analytics David P. Wilson and Marelize Görgens Introduction 27 Avoiding Inefficiency 30 Shortcomings of Traditional Cost-Effectiveness Analyses 33 The Optima Model for Choosing Interventions 35 Questions Answered through an Optima Analysis 42 Evolution of Optima Tools 42 Conclusions and Future Directions 47 Note 50 References 50 Chapter 2: Armenia 57 Mobilizing an HIV Response When a Key Population Is Mobile Samvel Grigoryan, Sherrie L. Kelly, Arshak Papoyan, Ruben Hovhannisyan, Trdat Grigoryan, David P. Wilson, Diego Cuadros, and Wendy Heard Briefly 57 Introduction 57 The Allocative Efficiency Analysis 64 Optimally Investing HIV Resources 66 Conclusions and Recommendations 71 Actions Taken and Next Steps 73 Notes 74 References 74 Chapter 3: Belarus 75 Changing HIV Budgets Based on Allocative Efficiency Analysis Alena Fisenka, Richard T. Gray, Pavel Yurouski, Vera Ilyenkova, David P. Wilson, Marelize Görgens, and Clemens Benedikt Briefly 75 Introduction 75 Contents | ix Initial Study Results and Their Interpretation 78 Reallocating Funds Based on Findings 86 Conclusions 92 Notes 92 Reference 92 Chapter 4: Bulgaria 93 Transitioning to Domestic Financing of HIV Programs amid High Costs Tonka Varleva, Hristo Taskov, Tsveta Raycheva, Emilia Naseva, Petar Tsintsarski, Nina Yancheva, Vyara Georgieva, Laura Grobicki, Jolene Skordis-Worrall, Feng Zhao, and Nejma Cheikh Briefly 93 Introduction 93 Funding Analysis Study 98 Allocative Efficiency Analysis Recommendations 103 Conclusions 105 Notes 106 References 106 Chapter 5: Georgia 109 An HIV Epidemic among Men Who Have Sex with Men Ketevan Stvilia, Irma Khonelidze, Hassan Haghparast- Bidgoli, Cliff C. Kerr, Feng Zhao, and Marelize Görgens Briefly 109 Introduction 110 The 2015 Allocative Efficiency Analysis 112 Allocative Efficiency Analysis Recommendations 122 Actions Taken and Next Steps 124 Notes 125 References 126 Chapter 6: Kazakhstan 129 Achieving Ambitious HIV Targets through Efficient Spending Andrew J. Shattock, Aliya Bokazhanova, Manoela Manova, Baurzhan S. Baiserkin, Irina Petrenko, David P. Wilson, Clemens Benedikt, and Nejma Cheikh x | Contents Briefly 129 Introduction 129 Efficiency Analysis Performed 133 Optimizing Allocations for Specific Targets 134 Policy Implications 141 Notes on the Modeling 144 Recommendations 145 Making Use of the Results 147 Notes 149 References 149 Chapter 7: Kyrgyz Republic 155 Addressing the HIV Treatment Gap Meerim Sarybaeva, Andrew J. Shattock, Talgat Mambetov, Larisa Bashmakova, Liutsiia Ianbukhtina, Manoela Manova, Richard T. Gray, Clemens Benedikt, and Katherine Ward Briefly 155 Introduction 155 Overview of the Epidemic 156 Funding for HIV Programming 158 Reducing New Infections and Deaths 160 Optima Analysis Findings 164 Actions Taken and Next Steps 169 Conclusions 178 Notes 179 References 180 Chapter 8: Moldova 181 Designing Efficient HIV Programs for Subnational HIV Epidemics Svetlana Plamadeala, Richard T. Gray, Iulian Oltu, Lucia Pirtina, Svetlana Popovici, Lilia Gantea, David P. Wilson, Alona Goroshko, and Clemens Benedikt Briefly 181 Introduction 182 HIV Allocative Efficiency Analysis 184 Understanding the HIV Epidemic 187 Allocative Efficiency Analysis Recommendations 200 Contents | xi Making Use of the Findings 202 Notes 204 References 204 Chapter 9: North Macedonia 207 Tackling a Small but Rapidly Growing Epidemic Vladimir Mikik, Laura Grobicki, Lidija Kirandjiska, Natasha Nikolovska Stankovikj, Jasmina Panovska-Griffiths, Feng Zhao, and Katherine Ward Briefly 207 Introduction 207 Projections from the Allocative Efficiency Analysis 210 Sustaining Effectiveness through Efficiency Gains 222 Allocative Efficiency Analysis Recommendations 224 Actions Taken and Next Steps 227 Notes 228 References 228 Chapter 10: Tajikistan 231 Toward a Rights-Based Response for Key
Recommended publications
  • Chronic Immune Activation Is the Cause of AIDS: Implication of Treatment in the Developing World
    Journal of Human Virology & Retrovirology Chronic Immune Activation is the Cause of AIDS: Implication of Treatment in the Developing World Opinion Abstract Volume 2 Issue 2 - 2015 Overwhelming number of evidence suggests that chronic immune system activation and dysregulation is responsible for progression into AIDS. Levels of activation Olga Malykhina* Liberal Arts and Sciences department, Devry University, markers on CD8+ and CD4+ T cells and other markers of activated immune response USA correlate with progression to AIDS. The uncontrolled inflammatory response has been associated with damage of lymphoid organs and the gastrointestinal mucosa; *Corresponding author: Olga Malykhina, Devry thus, further affecting T cell homeostasis and causing bacterial translocation, University visiting professor, 3300 N Campbell Ave, respectively. Immune system activation persists even after viral loads have been Chicago, IL, 60618, USA, Tel: 614-313-6343; Email: suppressed with antiretroviral therapy, which has been associated with increased [email protected] morbidity and mortality of patients. On the other hand, natural primate hosts of SIV display very little immune activation and do not progress to AIDS. Several studies Received: January 23, 2015 | Published: February 05, 2015 have been performed with immune suppressors and modifiers on HIV patients with varying degrees of success. The immune modifier that showed the most promise of being globally accessible and affordable HIV treatment is a probiotic. Probiotic treatment studies demonstrated safety and efficacy in maintaining T cell homeostasis of HIV-infected individuals. The probiotic also has the potential of being genetically manipulated to increase its effectiveness. An effective probiotic treatment for HIV infections has the potential of being grown locally in resource limited regions and by the users themselves; therefore, reducing cost of HIV treatment and prolonging the health of HIV-infected individuals.
    [Show full text]
  • Hiv Single Pill Sustained Efficacy at 48 Weeks1,2
    Discover this journal online at wileyonlinelibrary.com/journal/hiv single pill sustained efficacy at 48 weeks1,2 The first PI-based single tablet regimen (STR) for HIV-1 patients HIV MEDICINE EFFICACY RESISTANCE TOLERABILITY High virologic suppression** Contains darunavir, which Renal and bone safety at 48 weeks1,2 has a known high genetic profile consistent with 1 1,2 HIV barrier to resistance TAF and cobicistat For treatment- For treatment- Volume 19, Volume Supplement 2, April 2018, 1–160 Pages naïve patients* experienced patients‡ who may benefit from who may benefit from MEDICINE Symtuza’s resistance Symtuza’s resistance and efficacy profile, in and tolerability profile, a convenient STR1,2 in a convenient STR1,2 Volume 19, Supplement 2, April 2018 ISSN 1464–2662 SYMTUZASYMTUZA is indicated for the treatment of humahumann immunodeficiency virus typee 1 (HIV-1) infection in adults and adolescents (aged(aged 12 years and older with bodyy weight at least 40 kg).3 EDITORS Genotypic testing should guide the use of Symtuza.3 Brian Gazzard Jens Lundgren SYMTUZA® 800 mg/150 mg/200 mg/10 mg film-coated tablets monitoring with underlying chronic hepatitis, cirrhosis, pre-treatment transaminase elevations, PRESENTATIONS, PACK SIZES, MARKETING AUTHORISATION NUMBER(S) & BASIC especially during first months. Consider prompt interruption/discontinuation of Symtuza if NHS COSTS PRESCRIBING INFORMATION evidence of new/worsening liver dysfunction. Nephrotoxicity: potential risk from chronic Abstracts of the 4th Joint Conference of the British HIV ACTIVE INGREDIENT(S): darunavir, cobicistat, emtricitabine, tenofovir alafenamide. exposure to low levels of tenofovir alafenamide. Renal impairment: Cobicistat decreases PRESENTATIONS PACK MARKETING AUTHORISATION BASIC NHS estimated creatinine clearance.
    [Show full text]
  • Antiretroviral Price Reductions
    UNTANGLING THE WEB OF ANTIRETROVIRAL PRICE REDUCTIONS 18th Edition – July 2016 www.msfaccess.org PREFACE In this report, we provide an update on the key facets of HIV treatment access. It includes the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line and salvage regimens, and a summary of the opportunities for – and threats to – expanding access to affordable antiretroviral therapy (ART). There is a table with information on ARVs, including quality assurance, manufacturers and pricing on pages 55 to 57. THE MSF ACCESS CAMPAIGN In 1999, on the heels of Médecins Sans Frontières (MSF) being awarded the Nobel Peace Prize – and largely in response to the inequalities surrounding access to HIV/AIDS treatment between rich and poor countries – MSF launched the Campaign for Access to Essential Medicines. Its sole purpose has been to push for access to, and the development of, life-saving and life-prolonging medicines, diagnostics and vaccines for patients in MSF programmes and beyond. www.msfaccess.org MSF AND HIV Médecins Sans Frontières (MSF) began providing antiretroviral therapy to a small number of people living with HIV/AIDS in 2000 in projects in Thailand, South Africa and Cameroon. At the time, treatment for one person for one year cost more than US$10,000. With increased availability of low-cost, quality antiretroviral drugs (ARVs), MSF provides antiretroviral treatment to 240,100 people in 18 countries, implements treatment strategies to reach more people earlier in their disease progression, and places people living with HIV at the centre of their care.
    [Show full text]
  • Expenditures for the Care of HIV-Infected Patients in Rural Areas in China's Antiretroviral Therapy Programs
    UCLA UCLA Previously Published Works Title Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs Permalink https://escholarship.org/uc/item/7f0435d4 Journal BMC Medicine, 9(1) ISSN 1741-7015 Authors Zhou, Feng Kominski, Gerald F Qian, Han-Zhu et al. Publication Date 2011-01-17 DOI http://dx.doi.org/10.1186/1741-7015-9-6 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Zhou et al. BMC Medicine 2011, 9:6 http://www.biomedcentral.com/1741-7015/9/6 RESEARCHARTICLE Open Access Expenditures for the care of HIV-infected patients in rural areas in China’s antiretroviral therapy programs Feng Zhou1*, Gerald F Kominski2, Han-Zhu Qian3, Jiansheng Wang4, Song Duan5, Zhiwei Guo6, Xinping Zhao7 Abstract Background: The Chinese government has provided health services to those infected by the human immunodeficiency virus (HIV) under the acquired immunodeficiency syndrome (AIDS) care policy since 2003. Detailed research on the actual expenditures and costs for providing care to patients with AIDS is needed for future financial planning of AIDS health care services and possible reform of HIV/AIDS-related policy. The purpose of the current study was to determine the actual expenditures and factors influencing costs for untreated AIDS patients in a rural area of China after initiating highly active antiretroviral therapy (HAART) under the national Free Care Program (China CARES). Methods: A retrospective cohort study was conducted in Yunnan and Shanxi Provinces, where HAART and all medical care are provided free to HIV-positive patients. Health expenditures and costs in the first treatment year were collected from medical records and prescriptions at local hospitals between January and June 2007.
    [Show full text]
  • Report of the Attorney General
    U.S. Department of Justice Washington, D.C. 20530 Report of the Attorney General to the Congress of the United States on the Administration of the Foreign Agents Registration Act of 1938, as amended, for the six months ending June 30, 2018 Report of the Attorney General to the Congress of the United States on the Administration of the Foreign Agents Registration Act of 1938, as amended, for the six months ending June 30, 2018 TABLE OF CONTENTS INTRODUCTION ................................................... 1-1 AFGHANISTAN......................................................1 ALBANIA..........................................................2 ALGERIA..........................................................3 ANGOLA...........................................................4 ANTIGUA & BARBUDA................................................5 ARMENIA..........................................................6 ARUBA............................................................7 AUSTRALIA........................................................8 AUSTRIA..........................................................11 AZERBAIJAN.......................................................12 BAHAMAS..........................................................14 BAHRAIN..........................................................16 BANGLADESH.......................................................18 BARBADOS.........................................................19 BELGIUM..........................................................20 BERMUDA..........................................................21
    [Show full text]
  • State of the Art: AIDS and ECONOMICS
    IAEN ~ International AIDS-Economics Network State of the Art: AIDS AND ECONOMICS July 2002 This document features papers written by: Peter Badcock-Walters Tony Barnett Stefano Bertozzi Lori Bollinger Lisa DeMaria Lia Fernald Steven Forsythe P. Hale S.M. Hammer Ishrat Husain Robert Greener Juan-Pablo Gutierrez M.D. Kazatchkine Lilani Kumaranayake Bill McGreevey Jean-Paul Moatti Ken Morrison I. N’Doye Shanti Noreiga Majorie Opuni John Stover Beena Varghese Alan Whiteside Editor: Steven Forsythe Director of Planning and Finance, HIV/AIDS Sponsored by: POLICY Project, and Merck & Co., Inc. POLICY Project State of the Art: AIDS AND ECONOMICS July 2002 Editor: Steven Forsythe Director of Planning and Finance, HIV/AIDS The POLICY Project Executive Summary i Acknowledgements The POLICY Project wishes to thank the many authors who wrote the chapters in this document. We also wish to thank Merck & Co. Inc, which has made a con- tribution specifically towards the repro- duction of this document. In addition to this hard copy, Merck’s contribution also made it possible for this document to be reproduced electronically on a CD and on the International AIDS and Economics Network (IAEN) website, www.iaen.org. All of the authors voluntarily contributed their time, effort, and creative ideas in or- der to make this document possible. The opinions expressed herein are those of the authors and do not necessarily reflect the views of any of the contributing agencies. The POLICY Project is implemented by The Futures Group International in col- laboration with Research Triangle Insti- tute and the Centre for Development and Population Activities, with funding from the United States Agency for International Development.
    [Show full text]
  • Pepfar 2017 Annual Report
    PEPFAR 2018 ANNUAL REPORT TO CONGRESS 15 YEARS OF SAVING LIVES THROUGH AMERICAN GENEROSITY AND PARTNERSHIP THE UNITED STATES PRESIDENT’S EMERGENCY PLAN FOR AIDS RELIEF 15 Years of Bipartisan Leadership 2018 Annual Report to Congress CONTENTS Executive Summary . 4 Accelerating Access to HIV Treatment . 76 The World Before PEPFAR . 11 Rates of Adherence and Retention . 78 Accelerating Progress Toward Epidemic Control . 13 HIV/AIDS Guidance – New Guidelines: Impact on the Epidemic and Policy Change as Part of Delivering on the Vision . 14 Shared Responsibility . 80 Key Remaining Challenges . 24 HIV Burden and Treatment Response . 86 PEPFAR Strategy for Accelerating Progress Supportive Care . 91 Toward Epidemic Control . 27 Ensuring Pediatric Treatment and Psychosocial Conclusion . 28 Support So Children Can Thrive . 92 Increasing the Impact and Cost-Effectiveness of Addressing Tuberculosis/HIV Co-Infection . 99 Every Dollar Invested . 30 Leveraging Partnerships for Sustainability . 102 How PEPFAR Harnesses Data for Maximizing Cost Effectiveness and Impact: Controlling the Building a Safer, More Secure World Through HIV/AIDS Pandemic . 32 Strategic PEPFAR Health Investments . 104 How PEPFAR Documents Results . 35 Driving a Sustainability Agenda with Country Partners . 106 Global Trends in New HIV Infections . 38 Table 6: Operationalizing Sustainability . 107 HIV Infections Averted Due to PEPFAR and Global HIV Response . 45 The Sustainability Index and Dashboard – A Road Map to Transfer Responsibility . 109 Validating the Models . 45 Sustainable Financing as a Key Priority . 109 Global Prevalence: Refining PEPFAR’s Impact and Progress Toward Epidemic Control and Building a Data Platform . 110 Implications of Future Costs for a Sustained HIV/AIDS Response . 47 Table 6 .
    [Show full text]
  • HIV MEDICINE Published on Behalf of the British HIV Association and the European AIDS Clinical Society
    HIV MEDICINE Published on behalf of the British HIV Association and the European AIDS Clinical Society Editors Brian Gazzard, UK HINARI: Access to this journal is available free online within institutions Jens Lundgren, Denmark in the developing world through the HINARI initiative with the WHO. For information, visit www.who.int/hinari/en/ Editorial Board Wiley is a founding member of the UN-backed HINARI, AGORA, and OARE José Gatell, Spain initiatives. They are now collectively known as Research4Life, making online scientific content available free or at nominal cost to researchers in developing Margaret Johnson, UK countries. Please visit Wiley’s Content Access – Corporate Citizenship site: Jürgen Rockstroh, Germany http://www.wiley.com/WileyCDA/Section/id-390082.html Georg Behrens, Germany Ian Williams, UK Publisher and Business Correspondence Editorial Panel HIV Medicine is published by John Wiley & Sons Ltd: 9600 Francisco Antunes, Portugal Jeff Lazarus, Denmark Garsington Road, Oxford OX4 2DQ, UK. Tel: +44 (0)1865 776868, Fax: Jose Arribas, Spain Adriano Lazzarin, Italy +44 (0)1865 714591. Blackwell Publishing was acquired by John Wiley & Jason Baker, USA Paddy Mallon, Dublin Sons in February 2007. Wiley’s Corporate Citizenship initiative seeks to address the environmental, Georg Behrens, Germany Esteban Martinez, Spain social, economic, and ethical challenges faced in our business and which Jordi Blanch, Spain Frank Miedema, Netherlands are important to our diverse stakeholder groups. Since launching the Stéphane Blanche, France José M Miró, Spain initiative, we have focused on sharing our content with those in need, Ray Brettle, UK Amanda Mocroft, London enhancing community philanthropy, reducing our carbon impact, creating Françoise Brun-Vézinet, France Jean-Michel Molina, France global guidelines and best practices for paper use, establishing a vendor Alexandra Calmy, Switzerland Fiona Mulcahy, Ireland code of ethics, and engaging our colleagues and other stakeholders in our Richard Chaisson, USA Robert Murphy, USA efforts.
    [Show full text]
  • Costs of Streamlined HIV Care Delivery in Rural Ugandan and Kenyan Clinics in the SEARCH Study Starley B
    Costs of streamlined HIV care delivery in rural Ugandan and Kenyan clinics in the SEARCH Study Starley B. Shadea,b, Thomas Osmandb, Alex Luoa, Ronald Ainec, Elly Assurahd, Betty Mwebazac, Daniel Mwaie, Asiphas Owaraganisec, Florence Mwangwac, James Ayiekod, Douglas Blackf, Lillian B. Brownf, Tamara D. Clarkf, Dalsone Kwarisiimac, Harsha Thirumurthyg, Craig R. Cohenh, Elizabeth A. Bukusid, Edwin D. Charleboisb, Laura Balzeri, Moses R. Kamyaj, Maya L. Petersenk, Diane V. Havlirf and Vivek Jainf Objectives/design: As antiretroviral therapy (ART) rapidly expands in sub-Saharan Africa using new efficient care models, data on costs of these approaches are lacking. We examined costs of a streamlined HIV care delivery model within a large HIV test- and-treat study in Uganda and Kenya. Methods: We calculated observed per-person-per-year (ppy) costs of streamlined care in 17 health facilities in SEARCH Study intervention communities (NCT: 01864603) via micro-costing techniques, time-and-motion studies, staff interviews, and administrative records. Cost categories included salaries, ART, viral load testing, recurring goods/ services, and fixed capital/facility costs. We then modeled costs under three increas- ingly efficient scale-up scenarios: lowest-cost ART, centralized viral load testing, and governmental healthcare worker salaries. We assessed the relationship between com- munity-specific ART delivery costs, retention in care, and viral suppression. Results: Estimated streamlined HIV care delivery costs were $291/ppy. ART ($117/ppy for TDF/3TC/EFV [40%]) and viral load testing ($110/ppy for 2 tests/year [39%]) dominated costs versus salaries ($51/ppy), recurring costs ($5/ppy), and fixed costs ($7/ppy). Optimized ART scale-up with lowest-cost ART ($100/ppy), annual viral load testing ($24/ppy), and govern- mental healthcare salaries ($27/ppy), lowered streamlined care cost to $163/ppy.
    [Show full text]
  • Taking an Economic Approach to Evaluating HIV Programs in Australia
    Taking an Economic Approach to Evaluating HIV programs in Australia Jonathan Anderson Student Number 3056666 1 PLEASE TYPE THE UNIVERSITY OF NEW SOUTH WALES Thesis/Dissertation Sheet Surname or Family name: Anderson First name: Jonathan Other name/s:St Clair Abbreviation for degree as given in the University calendar: PhD School: The Kirby Institute Faculty:Medicine Title: Taking an economic approach to evaluating HIV programs in Australia Abstract 350 words maximum: (PLEASE TYPE) Research program aimed to assess whether Assessing Cost Effectiveness (ACE) approach could be used in priority­ setting process to assess interventions for treatment and prevention of HIV in Australia that stakeholders could understand and be engaged in, and that would provide insights that would be useful, relevant and illuminating. Three linked studies of ACE-HIV supported by two studies measuring cost and patient-reported outcomes of people living with HIV in Australia. Chapter 1 is literature review on HIV interventions in high-income countries. There were few published studies on economic evaluations of interventions for the prevention and treatment of HIV in Australia and few studies of interventions that were relevant in 2008. Chapter 2 reports study using a novel method to derive cost data for 10,951 people living with HIV from Medicare Australia. Data from this study were combined with other available data to estimate total cost of HIV healthcare in Australia for use in models of ACE-HIV project. Study found that it was possible to use Medicare Australia database to estimate costs of HIV healthcare claimed through the Medicare Benefits Schedule. Chapter 3 describes original study measuring health-related utility in people living with HIV in era of effective antiretrovirals.
    [Show full text]
  • U.S. Government Publishing Office Style Manual
    Style Manual An official guide to the form and style of Federal Government publishing | 2016 Keeping America Informed | OFFICIAL | DIGITAL | SECURE [email protected] Production and Distribution Notes This publication was typeset electronically using Helvetica and Minion Pro typefaces. It was printed using vegetable oil-based ink on recycled paper containing 30% post consumer waste. The GPO Style Manual will be distributed to libraries in the Federal Depository Library Program. To find a depository library near you, please go to the Federal depository library directory at http://catalog.gpo.gov/fdlpdir/public.jsp. The electronic text of this publication is available for public use free of charge at https://www.govinfo.gov/gpo-style-manual. Library of Congress Cataloging-in-Publication Data Names: United States. Government Publishing Office, author. Title: Style manual : an official guide to the form and style of federal government publications / U.S. Government Publishing Office. Other titles: Official guide to the form and style of federal government publications | Also known as: GPO style manual Description: 2016; official U.S. Government edition. | Washington, DC : U.S. Government Publishing Office, 2016. | Includes index. Identifiers: LCCN 2016055634| ISBN 9780160936029 (cloth) | ISBN 0160936020 (cloth) | ISBN 9780160936012 (paper) | ISBN 0160936012 (paper) Subjects: LCSH: Printing—United States—Style manuals. | Printing, Public—United States—Handbooks, manuals, etc. | Publishers and publishing—United States—Handbooks, manuals, etc. | Authorship—Style manuals. | Editing—Handbooks, manuals, etc. Classification: LCC Z253 .U58 2016 | DDC 808/.02—dc23 | SUDOC GP 1.23/4:ST 9/2016 LC record available at https://lccn.loc.gov/2016055634 Use of ISBN Prefix This is the official U.S.
    [Show full text]
  • Unaids Programme Coordinating Board
    UNAIDS PROGRAMME COORDINATING BOARD UNAIDS/PCB (33)/13.18 Issue date: 21 November 2013 THIRTY-THIRD MEETING Date: 17-19 December 2013 Venue: Executive Board Room, WHO, Geneva Agenda item 4 Strategic use of antiretroviral medicines for treatment and prevention of HIV Additional documents for this item: none Action required at this meeting - Recalling the commitment of member states under the 2011 Political Declaration on HIV/AIDS to accelerate efforts to achieve the goal of universal access to antiretroviral therapy for those eligible based on World Health Organization (WHO) HIV treatment guidelines that indicate timely initiation of quality assured treatment for its maximum benefit, the Programme Coordinating Board (PCB) is invited to: See decisions in paragraphs below: 132. Welcome this paper; 133. Call upon Member States to: a. Ensure that acceleration of access to HIV treatment, including addressing the barriers to treatment access, are factored into all stages of HIV and health planning, implementation, monitoring and evaluation, and resource mobilization, particularly with regards to development of investment thinking approach, and support for the roll-out of the New Funding Model of the Global Fund to Fight AIDS, TB and Malaria (Global Fund); b. implement the 2013 WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection; c. continue work towards further scale-up of access to HIV services including by strengthening community systems and the role of communities in creating demand and delivering services; d. work to ensure the sustainability of national AIDS responses recognizing the principles of country ownership through strengthening of shared responsibility, innovative sustainable financing to meet increased demand, building of strategic partnerships, and based on multi-sectoral approaches; e.
    [Show full text]